Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
INHIBITORS OF ANGIOGENIC FACTORS
Document Type and Number:
WIPO Patent Application WO/2022/089440
Kind Code:
A1
Abstract:
A recombinant human Fc fusion protein comprises an Ig-like domain of a first human VEGF receptor, another different Ig-like domain of a second human VEGF receptor, at least yet another Ig-like domain of a third human VEGF receptor, and the Fc portion of the human IgG1. The fusion protein is useful in treating or controlling an ocular disease, condition, or disorder that has etiology in aberrant angiogenesis.

More Like This:
JP6209206The epitope and its use on the surface antigen of an epidermal growth factor receptor
WO/2019/099838COMBINATION THERAPIES
JP4289790Mammalian potassium channel families with novel mechanical sensitivities activated by polyunsaturated fatty acids, and methods of using them specifically for pharmaceutical screening.
Inventors:
ZHANG JINZHONG (US)
SHEN WEI YONG (AU)
SEMBA CHARLES (US)
HU JOHN ZHENZE (US)
XIA ZHEN QI (US)
Application Number:
PCT/CN2021/126470
Publication Date:
May 05, 2022
Filing Date:
October 26, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ELUMINEX BIOSCIENCES SUZHOU LTD (CN)
International Classes:
C07K16/28; A61P35/00; C07K14/00; C12P21/00
Foreign References:
US20060030000A12006-02-09
CN102134277A2011-07-27
CN103319610A2013-09-25
CN109071670A2018-12-21
Other References:
DATABASE GenBank Protein ; ANONYMOUS : "VEGFR3 long form [Homo sapiens] ", XP055924832, retrieved from NCBI
Attorney, Agent or Firm:
JUN HE LAW OFFICES (CN)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: MULTIFUNCTIONAL ROWING EXERCISE MACHINE

Next Patent: CROSS-DEVICE CONTENT SHARING METHOD, ELECTRONIC DEVICE AND SYSTEM